顶峰治疗

关于 Summit Therapeutics

Summit Therapeutics, Inc. is a biopharmaceutical company, that 专注于 the discovery, 开发, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was 成立 in 2003 and is 总部位于 in Miami, FL.

成立时间

2003

首席执行官

Mr. Robert W. Duggan

员工人数

265

总部地址

Miami, Florida, United States of America

财年结束日

12-31

官方网站

smmttx.com

公司概况

交易所

US

股票代码

SMMT

市值排名

#1207

上市日期

2015-03-05

市值

11.67B

流通市值

2.23B

总股数

797.75M

流通股数

152.29M

行业与主题板块

浏览全部行业与主题板块